A single-centre, randomised, double-blind, placebo controlled Phase I study in two parts: Part A to assess a safe and tolerable supratherapeutic dose of TC-5214 after single ascending oral doses in healthy male subjects, followed by Part B: A four-period double-dummy crossover study to investigate the effect of 2 single doses (therapeutic and supratherapeutic) of TC-5214 on the QT/QTc interval, compared to placebo, using moxifloxacin (Avelox®) as a positive control, in healthy male subjects.
